Biotech Values

[drbio45]

It is amazing that everyone assumes that ariad will be able to do an open label study for the CML drug.

Chemgenex was able to do the open label study for the t315i mutation because there was no drug approved for that mutation.

If omapro is approved in early March for the t315i mutation the fda will not accept an open label study by ariad.

I own ariad because the upcoming data will probably be good but their trial will probably have to be used in conjunction with Omapro

all the better because their drug with omapro may actually turn into some cures.